PGEN Stock Overview
Operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Precigen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.30 |
| 52 Week High | US$1.93 |
| 52 Week Low | US$0.65 |
| Beta | 1.65 |
| 1 Month Change | 39.32% |
| 3 Month Change | 64.93% |
| 1 Year Change | -5.80% |
| 3 Year Change | -44.21% |
| 5 Year Change | -72.63% |
| Change since IPO | -94.74% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate
Feb 28
Precigen: RRP Targeting With AdenoVerse Technology Platform
Jan 20Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?
Nov 04Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?
Jul 18Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade
May 15Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio
Apr 18Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?
Nov 10Precigen names Rutul Shah as chief operating officer
Sep 21Circling Back On Precigen
Aug 23Is Precigen (NASDAQ:PGEN) Using Too Much Debt?
Aug 10Precigen Q2 2022 Earnings Preview
Aug 07Precigen to sell Trans Ova Genetics for $170M upfront
Jul 05Shareholder Returns
| PGEN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 15.0% | 2.1% | -0.2% |
| 1Y | -5.8% | -3.6% | 23.7% |
Return vs Industry: PGEN underperformed the US Biotechs industry which returned -3.6% over the past year.
Return vs Market: PGEN underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| PGEN volatility | |
|---|---|
| PGEN Average Weekly Movement | 15.3% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: PGEN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PGEN's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 202 | Helen Sabzevari | precigen.com |
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification.
Precigen, Inc. Fundamentals Summary
| PGEN fundamental statistics | |
|---|---|
| Market cap | US$371.94m |
| Earnings (TTM) | -US$139.56m |
| Revenue (TTM) | US$3.96m |
96.1x
P/S Ratio-2.7x
P/E RatioIs PGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PGEN income statement (TTM) | |
|---|---|
| Revenue | US$3.96m |
| Cost of Revenue | US$53.07m |
| Gross Profit | -US$49.11m |
| Other Expenses | US$90.46m |
| Earnings | -US$139.56m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.48 |
| Gross Margin | -1,239.14% |
| Net Profit Margin | -3,521.68% |
| Debt/Equity Ratio | 0% |
How did PGEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/29 23:31 |
| End of Day Share Price | 2025/01/29 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Precigen, Inc. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Huang | Barclays |
| Derik de Bruin | BofA Global Research |
| Justin Walsh | B. Riley Securities, Inc. |